EXCEPTIONAL SAFETY PROFILE

Axona® is manufactured and distributed in accordance with strict Food and Drug Administration (FDA) guidelines. This medical food product is administered under supervision of a licensed healthcare professional and dispensed by prescription only. It can be taken alone or with commonly prescribed Alzheimer’s disease medications (acetylcholinesterase inhibitors and NMDA receptor antagonists). In addition, the main ingredient in Axona has achieved self-affirmed Generally Recognized As Safe (GRAS) designation, the highest standard of safety for foods. Other ingredients are also GRAS or are FDA-approved food additives.

  • Low incidence of adverse events1
  • The most common adverse events were diarrhea, flatulence, and dyspepsia.
  • Can be taken with commonly prescribed Alzheimer’s medications
  • Axona can be taken with commonly prescribed medications for Alzheimer’s disease.
  • Approximately 80% of clinical trial participants were taking at least one prescription AD medication. The most commonly prescribed medications were acetylcholinesterase (AChE) inhibitors such as Aricept® (donepezil HCl) and/or N-methyl-Daspartic acid (NMDA) receptor antagonists such as Namenda® (memantine HCl).

Little effect on cholesterol2

In an idependent study, no significant differences were noted in the concentrations of serum total cholesterol, very low-density lipoprotein cholesterol, LDL cholesterol, or HDL cholesterol between 40 grams of medium-chain triglycerides (twice the regularly prescribed amount) and 40 grams of long-chain triacylglycerols (blended vegetable oil).

Important Safety Information

Axona should be used with caution in patients at risk for ketoacidosis, a history of inflammation of the gastrointestinal system, metabolic syndrome, uncontrolled diabetes, and/or renal dysfunction. Axona contains caseinate and whey, and lecithin. Thus, CONTAINS MILK AND SOY.

Please see medical food full prescribing information HERE.

Aricept is a registered trademark of Eisai Co., Ltd. Namenda is a registered trademark of Forest Laboratories, Inc.

References: 1. Axona [Prescribing Information]. Broomfield, CO: Accera, Inc.; September 2009. 2. St-Onge MP, Bosarge A, Goree LL, Darnell B. Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil. J Am Coll Nutr. 2008;27(5):547-552.